Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

NCT00021723 is registered in ClinicalTrials.gov with JANSSEN Alzheimer Immunotherapy Research & Development, LLC as lead sponsor.

NCT NCT00021723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00021723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2001
Completion date
September 30, 2003
Enrollment
375
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease